In 1971, President Nixon declared drug abuse “public enemy number one,” launching what became a multi-decade domestic and international campaign of criminalization that would reshape American society and foreign policy. Cannabis — long used medicinally and recreationally — was placed in the most restrictive federal drug category where it remains more than five decades later. The human costs of that decision are well documented. This is the complete history.
- Nixon’s own adviser John Ehrlichman acknowledged in 1994 (published 2016) that the War on Drugs was designed to target Black communities and antiwar protesters, not addiction
- Cannabis was placed in Schedule I in 1970 as a temporary measure; the Shafer Commission recommended decriminalization in 1972 and was ignored
- The US has spent over $1 trillion on drug enforcement since 1971 (Drug Policy Alliance estimate)
- The FBI recorded 522,000 cannabis arrests in 2019, with 92% for simple possession — not trafficking or distribution
- Black Americans are 3.73 times more likely to be arrested for cannabis possession than white Americans despite similar usage rates (ACLU, 2020)
- As of 2026, 24 states plus DC have adult-use legal cannabis, creating a de facto policy reality that increasingly contradicts federal Schedule I status
Origins: Before the War on Drugs
Cannabis was legal and widely used in the United States well into the 20th century. It appeared in the US Pharmacopeia from 1850 to 1942 as a treatment for conditions ranging from neuralgia to tetanus. The first federal cannabis restriction came through the Marihuana Tax Act of 1937, which effectively criminalized cannabis by imposing prohibitive transfer taxes — passed with racially-coded testimony about “Marihuana” driving Mexican immigrants and Black jazz musicians to violence.
State-level criminalization accelerated through the 1950s. The Narcotic Control Act of 1956 established mandatory minimum sentences for drug offenses for the first time: 2–10 years for first-offense possession, 5–20 years for first-offense sale.
The Controlled Substances Act and Schedule I
The Controlled Substances Act of 1970 created the federal drug scheduling framework that still governs US drug policy. Drugs are ranked in five schedules based on two criteria: potential for abuse and accepted medical use. Schedule I is the most restrictive category: high abuse potential, no accepted medical use, and no safe use even under medical supervision.
Cannabis was temporarily placed in Schedule I while the Shafer Commission — a bipartisan presidential commission — studied the question. In 1972, the Shafer Commission released its report “Marihuana: A Signal of Misunderstanding,” recommending decriminalization of personal possession and private use. President Nixon rejected the report and kept cannabis in Schedule I. It has remained there ever since.
“We knew we couldn’t make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities.”
— John Ehrlichman, Nixon Domestic Policy Chief, in a 1994 interview published in Harper’s Magazine, 2016
Schedule I Classification: What It Means
| Schedule | Criteria | Examples |
|---|---|---|
| Schedule I | High abuse potential; no accepted medical use | Heroin, cannabis, LSD, psilocybin, MDMA |
| Schedule II | High abuse potential; accepted medical use with restrictions | Oxycodone, fentanyl, cocaine, methamphetamine, Adderall |
| Schedule III | Moderate abuse potential; accepted medical use | Anabolic steroids, ketamine, buprenorphine |
| Schedule IV | Lower abuse potential; accepted medical use | Xanax, Valium, Ambien, tramadol |
| Schedule V | Lowest abuse potential; accepted medical use | Cough suppressants with codeine, pregabalin |
The apparent contradiction: cocaine and methamphetamine (Schedule II) have more accepted medical use under federal law than cannabis (Schedule I) — cocaine as a topical anesthetic in ENT procedures, methamphetamine as a prescription ADHD treatment (Desoxyn). Meanwhile, FDA-approved CBD (Epidiolex) is prescribed by doctors across the country while its source plant remains Schedule I.
Racial Disparities in Cannabis Enforcement
The ACLU’s 2020 report “A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform” analyzed FBI arrest data across all 50 states from 2010 to 2018. Key findings:
- Black Americans are 3.73 times more likely to be arrested for cannabis possession than white Americans nationally, despite comparable usage rates
- In some states (Montana, Kentucky, Illinois before legalization), the Black-to-white arrest ratio exceeds 6:1 or even 9:1
- In 31 states, racial cannabis arrest disparities are greater than the national average
- These disparities persist in states with decriminalization laws, because decriminalization reduces but does not eliminate police encounters and enforcement
- In New York City, Black and Latino residents accounted for 94% of cannabis possession arrests in 2018 despite representing under 55% of the population
Usage rates between Black and white Americans are statistically similar (SAMHSA National Survey on Drug Use and Health). The disparity in arrest rates is driven by enforcement targeting, not use frequency.
Reform Timeline: Decriminalization to Legalization
International Impact of US Drug Policy
The US War on Drugs extended far beyond its borders through the State Department, DEA international operations, and foreign aid conditions. Key international consequences:
- Colombia and the Andean Initiative: The US channeled over $2.5 billion to Colombia for drug eradication from 1989–2003. Aerial fumigation of coca crops displaced hundreds of thousands of farmers. Drug production shifted production areas but was not eliminated.
- Mexico’s Cartels: Prohibition created the economic conditions for drug trafficking organizations to grow into paramilitary forces. The Merida Initiative provided $3+ billion in US security aid to Mexico from 2008 onward to fight cartel violence directly linked to prohibition-created black markets.
- Southeast Asia: US pressure maintained harsh cannabis laws across Thailand, Indonesia, and the Philippines for decades. Thailand became the first Southeast Asian country to legalize cannabis in 2022 (medical), reversing course after pressure from its own agricultural sector.
- UN Drug Treaties: The 1961 Single Convention on Narcotic Drugs, heavily influenced by US policy priorities, required signatory nations to criminalize cannabis, spreading prohibition globally. Bolivia was threatened with aid cuts when it sought to protect traditional coca leaf use.
Related Guides
Frequently Asked Questions
Why is cannabis still Schedule I federally?
Cannabis was placed in Schedule I in 1970 as a temporary measure while the Shafer Commission studied the issue. The Commission recommended decriminalization in 1972, but Nixon rejected it. Cannabis has remained Schedule I despite state medical programs, FDA approval of CBD (Epidiolex), and decades of research. The DEA proposed rescheduling to Schedule III in 2024.
How much has the War on Drugs cost?
The Drug Policy Alliance estimates the US has spent over $1 trillion on drug enforcement since 1971. Annual federal drug enforcement spending exceeds $50 billion when combining DEA operations, incarceration, and interdiction. The FBI recorded 522,000 cannabis arrests in 2019, with 92% for simple possession.
Are Black and Latino people disproportionately arrested for cannabis?
Yes. The ACLU’s 2020 report found Black Americans are 3.73 times more likely to be arrested for cannabis possession than white Americans despite similar usage rates. In some states the ratio exceeds 6:1. In New York City, Black and Latino residents accounted for 94% of cannabis possession arrests in 2018.
What is the current status of federal cannabis reform?
As of 2026, cannabis remains federally Schedule I but the DEA proposed rescheduling to Schedule III in 2024 — the first proposed federal change since 1970. Rescheduling would not legalize cannabis but would remove the 280E tax burden on cannabis businesses and facilitate federally approved research. Over 24 states plus DC have adult-use legal cannabis.